14 completed, 2 not yet recruiting, 2 recruiting, 2 withdrawn. 17 Phase 2, 6 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Completed 12, Withdrawn 2, Not yet recruiting 1, Recruiting 1, Unknown 1 |
| Phase 3 | 6 | Completed 3, Not yet recruiting 1, Recruiting 1, Terminated 1 |
| Phase 1 | 2 | Completed 2 |
Follow Can-Fite BioPharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-label, Phase 2 Pilot Study on the Efficacy and Safety of Piclidenoson in Patients With Lowe Syndrome Piclidenoson - Lowe Syndrome | Phase 2 | Not yet recruiting | Can-Fite BioPharma | 5 | 2026-06-01 | 2026-02-18 |
| A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy piclidenoson, Placebo - Plaque Psoriasis | Phase 3 | Not yet recruiting | Can-Fite BioPharma | 705 | 2025-06-01 | 2025-04-29 |
| Namodenoson Treatment of Advanced Pancreatic Cancer Namodenoson 25mg - Pancreatic Adenocarcinoma, Pancreatic Cancer | Phase 2 | Recruiting | Can-Fite BioPharma | 20 | 2024-11-10 | 2025-01-31 |
| Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis Namodenoson, Placebo - Hepatocellular Carcinoma, Cirrhosis | Phase 3 | Recruiting | Can-Fite BioPharma | 471 | 2023-03-15 | 2025-04-29 |
| Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH) Namodenoson, Placebo - NASH - Nonalcoholic Steatohepatitis | Phase 2 | Unknown | Can-Fite BioPharma | 114 | 2021-12-10 | 2024-07-31 |
| Piclidenoson for Treatment of COVID-19 Piclidenoson, Placebo - COVID-19, Coronavirus Infection | Phase 2 | Completed | Can-Fite BioPharma | 6 | 2021-01-06 | 2022-04-22 |
| Safety &Efficacy of CF101 to Subjects With Uveitis CF101, Placebo - Uveitis, Posterior, Uveitis, Intermediate | Phase 2 | Withdrawn | Can-Fite BioPharma | 2019-01-01 | 2018-02-01 | |
| A Study of the Efficacy and Safety of CF101 to Patients With Osteoarthritis of the Knee CF101, Placebo - Osteoarthritis of the Knee | Phase 2 | Withdrawn | Can-Fite BioPharma | 2018-11-01 | 2018-02-01 | |
| CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis CF101 2mg, CF101 3mg, Apremilast 30mg - Plaque Psoriasis | Phase 3 | Completed | Can-Fite BioPharma | 528 | 2018-09-15 | 2022-06-28 |
| A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease CF102, Placebo - Non-alcoholic Steatohepatitis (NASH) | Phase 2 | Completed | Can-Fite BioPharma | 60 | 2017-11-27 | 2020-03-17 |
| CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis CF101 1 mg, CF101 2 mg, Placebo - Rheumatoid Arthritis | Phase 3 | Terminated | Can-Fite BioPharma | 244 | 2017-10-30 | 2020-12-19 |
| Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC) CF102, Placebo - Hepatocellular Carcinoma | Phase 2 | Completed | Can-Fite BioPharma | 78 | 2014-09-01 | 2022-10-04 |
| Trial of CF101 to Treat Patients With Dry Eye Disease CF101 - Keratoconjunctivitis Sicca | Phase 3 | Completed | Can-Fite BioPharma | 236 | 2011-07-01 | 2022-06-30 |
| Trial of CF101 to Treat Patients With Psoriasis CF101, Placebo - Plaque Psoriasis | Phase 2 / Phase 3 | Completed | Can-Fite BioPharma | 293 | 2011-07-01 | 2020-11-18 |
| Oral CF101 Tablets Treatment in Patients With Rheumatoid Arthritis CF101, Placebo control - Rheumatoid Arthritis | Phase 2 | Completed | Can-Fite BioPharma | 79 | 2010-10-01 | 2022-05-24 |
| Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure CF101, Placebo for - Ocular Hypertension, Glaucoma | Phase 2 | Completed | Can-Fite BioPharma | 89 | 2010-10-01 | 2022-05-12 |
| A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1 CF 102, Placebo - Chronic Hepatitis C | Phase 1 / Phase 2 | Completed | Can-Fite BioPharma | 32 | 2009-07-01 | 2015-04-15 |
| A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma CF102 - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Completed | Can-Fite BioPharma | 19 | 2009-02-01 | 2022-05-17 |
| Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis Patients CF101, Placebo - Rheumatoid Arthritis | Phase 2 | Completed | Can-Fite BioPharma | 253 | 2008-02-01 | 2018-03-29 |
| Safety and Efficacy Study of CF101 to Treat Psoriasis CF101 1mg, CF101 2mg, CF101 4mg - Plaque Psoriasis | Phase 2 | Completed | Can-Fite BioPharma | 76 | 2007-06-01 | 2023-02-08 |
Showing 20 of 22. Sign in to see all of them.
Arthritis, Rheumatoid (4) · Carcinoma, Hepatocellular (3) · Psoriasis (3) · Dry Eye Syndromes (2) · Keratoconjunctivitis Sicca (2) · Non-alcoholic Fatty Liver Disease (2) · COVID-19 (1) · Coronavirus Infections (1) · Fibrosis (1) · Glaucoma (1) · Hepatitis C (1) · Hepatitis C, Chronic (1) · Liver Neoplasms (1) · Ocular Hypertension (1) · Oculocerebrorenal Syndrome (1)
CF101 (13) · N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine (11) · 2-chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide (6) · Sugars (1) · apremilast (1)
Israel (20) · Bulgaria (10) · Romania (8) · Serbia (7) · Poland (5) · Bosnia and Herzegovina (4) · Moldova (4) · United States (4) · Canada (2) · Ukraine (2) · Croatia (1) · Czechia (1) · Italy (1) · Slovakia (1)
Michael H Silverman, MD (14) · Michael David, MD (2) · Irit Bareket, MD (1) · Michael H Silverman (1) · Salomon M Stemmer, MD (1) · Salomon Shtemmer, MD (1) · Zivit Harpaz (1)
PMID 20304499, PMID 21504485, PMID 23299770, PMID 34671996, PMID 35092056, PMID 38279575